IBI323 + chemotherapy

IBI323 + chemotherapy is a combination regimen of the bispecific antibody **IBI323** with standard cytotoxic chemotherapy agents. IBI323 is a recombinant bispecific monoclonal antibody that simultaneously targets **Programmed cell death ligand 1 (PD-L1)** and **Lymphocyte-activation gene 3 (LAG-3)**, both of which are immune checkpoint proteins exploited by cancers to escape immune surveillance. By blocking both PD-1/PD-L1 and LAG-3/MHC-II interactions, IBI323 aims to stimulate stronger anti-tumor T cell immunity compared to monotherapy or dual antibody combinations, and it possesses an additional cell bridging function that can bring tumor cells and immune T cells into closer contact. Preclinical studies show enhanced efficacy and greater activation of tumor-specific CD8+ and CD4+ T cells, with durable responses. This combination therapy is being tested for advanced malignant tumors, particularly where patients have progressed on standard therapies[1][2][4][5].